ClinicalTrials.gg
CompletedNCT07019883Updated Jun 12, 2026

A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults

A Phase 1 interventional study of H5 AC-Anhui RNA Vaccine and H5 Astrakhan RNA Vaccine in Avian Influenza, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 3 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Influenza in Birds by National Institute of Allergy and Infectious Diseases (NIAID) — none open to participants now, none under way, none of them phase 3. Influenza in Birds · National Institute of Allergy and Infectious Diseases (NIAID).

Enrollment
24th of 43
80 · median 95
Started
2025
the only one that year
Phase 1
23 of 45
none open now
Registered
45th of 45
by date

Among the 45 studies in Influenza in Birds by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 24th largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2025, is one of 23 in phase 1, and was the 45th registered.

Influenza in Birds

96 studies on the registry are indexed under Influenza in Birds; 2 are open to participants now.

Browse Influenza in Birds studies →

Open to participants now

None of the 45 studies in Influenza in Birds by National Institute of Allergy and Infectious Diseases (NIAID) is open now. The open studies under Influenza in Birds, anywhere →

Who these studies take

Of the 1 Influenza in Birds study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies in Influenza in Birds by National Institute of Allergy and Infectious Diseases (NIAID) as a file.
02

Study summary

This is a phase 1, multicenter, randomized, double-blind trial of two influenza A/H5 mRNA-based vaccines on healthy adult participants, 18-49 years of age. Stage 1 will serve as the open-label, dose finding stage. The first 10 participants will receive 12.5 mcg of H5 AC-Anhui RNA vaccine (Group 1), and the second 10 participants will receive 25 mcg of H5 AC-Anhui RNA vaccine (Group 2). After Protocol Safety Review Team (PSRT) review of reactogenicity and safety data through Day 8 for both Groups 1 and 2, another 10 participants may be enrolled to receive 50 mcg of H5 AC-Anhui RNA vaccine (Group 3). Safety data from 7 days after dose 2 for Groups 1 and 2 participants will be reviewed by the PSRT prior to clearing Group 3 participants for the second dose of vaccine. Individual participants will be followed for approximately 6 months following the second dose of vaccine. The primary objective is to assess the safety of two doses of H5 AC-Anhui RNA vaccine or H5-Astrakhan RNA vaccine administered intramuscularly in healthy adults (18-49 years). Once the Day 36 data from Group 3 are reviewed by the PSRT, a dose will be chosen (12.5 mcg, 25 mcg, or 50 mcg) for advancement to Stage 2 where 50 participants will be randomized 1:1 to receive either H5 AC-Anhui RNA (Group 4) or H5 Astrakhan RNA (Group 5) in a double-blinded manner.

Read the detailed description

This is a multicenter, randomized, double-blind trial of two influenza A/H5 mRNA-based vaccines. The trial population consists of healthy adult participants, 18-49 years of age. Stage 1 will serve as the open-label, dose finding stage. The first 10 participants will receive 12.5 mcg of H5 AC-Anhui RNA vaccine (Group 1), and the second 10 participants will receive 25 mcg of H5 AC-Anhui RNA vaccine (Group 2). These groups will be enrolled sequentially without pause unless study halting rules are triggered. After Protocol Safety Review Team (PSRT) review of reactogenicity and safety data through Day 8 for both Groups 1 and 2, another 10 participants may be enrolled to receive 50 mcg of H5 AC-Anhui RNA vaccine (Group 3). Safety data from Day 36 (7 days after dose 2) for Groups 1 and 2 participants will be reviewed by the PSRT prior to clearing Group 3 participants for the second dose of vaccine. Once the Day 36 data from Group 3 are reviewed by the PSRT, a dose will be chosen (12.5 mcg, 25 mcg, or 50 mcg) for advancement to Stage 2 where 50 participants will be randomized 1:1 to receive either H5 AC-Anhui RNA (Group 4) or H5 Astrakhan RNA (Group 5) in a double-blinded manner. Participants will be randomized on the day of enrollment. Screening and enrollment can occur on the same day. Individual participants will be followed for approximately 6 months following the second dose of vaccine.

The primary objective is to assess the safety of two doses of H5 AC-Anhui RNA vaccine or H5-Astrakhan RNA vaccine administered intramuscularly in healthy adults (18-49 years). The secondary objective is to assess the serum antibody responses to H5 AC-Anhui RNA vaccine or H5-Astrakhan RNA vaccine.

03

Conditions studied

  • Avian Influenza

Keywords

  • H5N1
  • Healthy Adults
  • Influenza
  • Novel H5 Central Antigen mRNA-LNP
  • Phase 1
  • Safety and Immunogenicity
  • Vaccine
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provides written prior to the initiation of any trial procedures
  2. Can understand and agrees to comply with all planned trial procedures and be available for all study visits
  3. Adult volunteers, age 18-49 years, inclusive, at time of enrollment.
  4. In good general health.* * Good health is defined by the absence of a medical condition described in the exclusion criteria. If the participant has another current, ongoing medical condition, the condition cannot meet any of the following criteria:

    1. was first diagnosed within 3 months of enrollment with a condition, in the opinion of investigator
    2. had non-elective surgery, clinically significant medical procedure, or hospitalization within 3 months of enrollment;
    3. received new prescription for systemic medication within 30 days of enrollment, unless the new prescription is in the same class of agent or a transition from generic to/from brand name equivalent; or
    4. takes medication that may pose a risk to participant's safety or impede assessment of adverse events or study endpoints if they participate in the study.
  5. Participants of * must agree to use or have practiced true abstinence** or use at least one acceptable primary form of .*** *These criteria apply to females who are in a heterosexual relationship who are of childbearing potential. Participants not of childbearing potential include females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, tubal ligation/salpingectomy, or permanently implanted contraceptive device placement).

    **True abstinence is complete lack of penile-vaginal intercourse. Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods.

    ***Acceptable forms of primary contraception include monogamous relationship with a vasectomized partner who has been vasectomized for 180 days or more prior to the participant's vaccination; intrauterine devices; birth control pills; and injectable/implantable/insertable/transdermal hormonal birth control products. Participants must have used >/=1 acceptable primary form of contraception for at least 30 days prior to vaccination and agree to continue >/=1 acceptable primary form of contraception through 60 days after last vaccination.

  6. Must agree to refrain from donating blood or blood products during the first 6 months of the study
  7. (BMI) 18 kg/m\^2 to 35 kg/m\^2, inclusive, and a weight of 130 kg or less at the time of screening

Exclusion criteria

Exclusion Criteria:

  1. Positive pregnancy test at screening or prior to vaccine dose
  2. Participant who is lactating
  3. Presence of a significant psychiatric condition that, in the opinion of the site Principal Investigator (PI) or appropriate sub-investigator, precludes study participation
  4. History of drug abuse or alcohol abuse within 6 months of enrollment that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation
  5. Has a significant acute illness (with or without fever), as determined by the site PI or appropriate sub-investigator, within 72 hours prior to dosing* *If the participant meets all other eligibility criteria, they may be enrolled and dosed once they meet this eligibility criterion. If the illness resolves within the 28-day screening window, they do not need to be rescreened, otherwise they will need to be rescreened
  6. Currently enrolled in or plans to participate in another clinical trial with an agent
  7. Has a history of anaphylaxis to any drug compound, vaccine, food, or other substance, unless approved by the Investigator (or designee)**

    **Sensitivity to components of the study product is exclusionary.

  8. Received any live-attenuated or mRNA vaccine in the 28 days prior or any other vaccine in the 14 days prior to study vaccination
  9. Has used any prohibited medication within 30 days prior to Day 1 or plans to use prohibited medications*** through Day 57

    ***Prohibited medications include systemic drugs, immune modulators (except acetaminophen or non-steroidal anti-inflammatory drugs), oral , and systemic antineoplastic agents. Topical, inhaled, and intranasal steroids, as well as topical anti-neoplastic agents are acceptable

  10. Abnormal blood pressure or temperature (Grade 1 or higher) at time of vaccination

    ****Grade 1 or higher is equivalent to: Systolic blood pressure (SBP) > 140 mmHg or \< 90 mmHg Diastolic blood pressure (DBP) > 90 mmHg Oral temperature >/= 38.0 degrees Celsius (100.4 degrees Fahrenheit)

  11. Abnormal heart rate (Grade 2 or higher) at time of vaccination
  12. Known and current (HIV), virus (HBV), or virus (HCV) infection, based on medical history
  13. Extended exposure (e.g., occupational or home exposure) to cattle or poultry since March 1, 2024
  14. Ingestion of non-pasteurized milk since March 1, 2024, or plans to drink non-pasteurized milk during participation in the trial
  15. Prior receipt of an influenza A/H5 vaccine
  16. History of myocarditis or pericarditis
  17. Has any medical disease or condition***** that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation****** *****Medical conditions include, but are not limited to, kidney disease with \< 89 mL/min/1.73 cm2 Chronic Kidney Disease Epidemiology Collaboration method (); known active liver disease; ischemic heart disease, cardiac conduction disorder, arrythmia requiring treatment, congenital long syndrome, uncompensated heart failure; diabetes requiring insulin; neuropathy or myopathy; history of Guillain-Barré Syndrome; and (not including squamous cell skin cancer, basal cell skin cancer, or cervical lowgrade squamous intraepithelial lesions) ******Participation may be precluded due to safety concern or inability to adequately evaluate clinical trial endpoints.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Stage 1 Group 1

    Healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 Antigenically Central (AC)-Anhui RNA Vaccine at 12.5 mcg on days 1 and 29. N=10

    Biological: H5 AC-Anhui RNA Vaccine · Other: Sodium Chloride, 0.9%

  • Experimental
    Stage 1 Group 2

    Healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 AC-Anhui RNA Vaccine at 25 mcg on days 1 and 29. N=10

    Biological: H5 AC-Anhui RNA Vaccine · Other: Sodium Chloride, 0.9%

  • Experimental
    Stage 1 Group 3

    After the Protocol Safety Review Team (PSRT) reviews the reactogenicity and safety data, through Day 8, for both Stage 1 Group 1 and Stage 1 Group 2, healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 AC-Anhui RNA Vaccine at 50 mcg on days 1 and 29. N=10

    Biological: H5 AC-Anhui RNA Vaccine · Other: Sodium Chloride, 0.9%

  • Experimental
    Stage 2 Group 4

    Following the Day 36 Stage 1 Group 3 data review by the Protocol Safety Review Team (PSRT), healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 AC-Anhui RNA Vaccine at 25 mcg on days 1 and 29. N=25

    Biological: H5 AC-Anhui RNA Vaccine · Other: Sodium Chloride, 0.9%

  • Experimental
    Stage 2 Group 5

    Following the Day 36 Stage 1 Group 3 data review by the Protocol Safety Review Team (PSRT), healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 Astrakhan RNA Vaccine at 25 mcg on days 1 and 29. N=25

    Biological: H5 Astrakhan RNA Vaccine · Other: Sodium Chloride, 0.9%

Interventions

  • BiologicalH5 AC-Anhui RNA Vaccine

    A nucleoside-modified mRNA vaccine encoding a stabilized, antigenically central hemagglutinin (HA) from influenza A(H5), based on A/Anhui/1/2005 (clade 2.3.4) with substitutions 222QL, 224GS, 156TA, and 134TA. The 2119-nt mRNA is encapsulated in lipid nanoparticles (LNPs) for intramuscular delivery.

  • BiologicalH5 Astrakhan RNA Vaccine

    The vaccine product consists of a monovalent nucleoside-modified mRNA that encodes a traditionally selected avian influenza HA. The H5 Astrakhan RNA encodes the HA from the clade 2.3.4.4b A/Astrakhan/3212/2020 virus.

  • OtherSodium Chloride, 0.9%

    0.9% Sodium Chloride Injection

06

What researchers measure

Primary outcomes

  1. Number and Percentage of participants experiencing any adverse events of special interest (AESI)

    Time frame: Through 90 days after second vaccination

  2. Number and Percentage of participants experiencing any medically attended adverse events (MAAE)

    Time frame: Through 6 months following the second dose

  3. Number and Percentage of participants experiencing any non-serious unsolicited adverse events (AEs)

    Time frame: Through 28 days following each dose

  4. Number and Percentage of participants experiencing any serious adverse events (SAE)

    Time frame: Through 6 months following the second dose

  5. Number and Percentage of participants experiencing new-onset chronic medical conditions (NOCMC)

    Time frame: Through 6 months following the second dose

  6. Number and Percentage of participants experiencing solicited local reactogenicity adverse events (AEs)

    Time frame: Through 7 days following each dose

  7. Number and Percentage of participants experiencing solicited systemic reactogenicity adverse events (AEs)

    Time frame: Through 7 days following each dose

  8. Number and Percentage of participants with clinical laboratory adverse events (AEs)

    Time frame: Through 7 days following each dose

Secondary outcomes

  1. Geometric mean fold rise (GMFR) in Group 1-specific anti-stalk serum antibodies since pre-vaccination (Day 1)

    Time frame: Day 8 through Day 57

  2. Geometric mean fold rise (GMFR) in homologous and heterologous H5-specific Neut antibody since pre-vaccination (Day 1)

    Time frame: Day 8 through Day 57

  3. Geometric mean fold rise in homologous and heterologous H5-specific Hemagglutination Inhibition Antibody (HAI) antibody since pre-vaccination

    Time frame: Day 8 through Day 57

  4. Geometric mean titers of Group 1-specific anti-stalk serum antibodies

    Time frame: Day 1 through Day 57

  5. Geometric mean titers of homologous and heterologous H5-specific hemagglutinin inhibition (HAI) antibodies

    Time frame: Day 1 through Day 57

  6. Geometric mean titers of homologous and heterologous H5-specific neutralizing antibodies (Neut)

    Time frame: Day 1 through Day 57

  7. Number and Percentage of participants achieving Hemagglutination Inhibition Antibody (HAI) titer seroconversion since pre-vaccination (Day 1) against the homologous and heterologous H5-specific hemagglutinin

    Seroconversion is defined as either a pre-vaccination titer \<1:10 and a post-vaccination titer \>/=1:40 or a pre- vaccination titer \>/=1:10 and a minimum four-fold rise in post-vaccination antibody titer

    Time frame: Day 8 through Day 57

  8. Number and Percentage of participants demonstrating Hemagglutination Inhibition Antibody (HAI) titer seroprotection against homologous and heterologous H5-specific hemagglutinin

    Seroprotection defined as \>/=1:40 titer

    Time frame: Day 1 through Day 57

  9. The number and percentage of participants achieving Neut seroconversion since pre-vaccination (Day 1) against the homologous and heterologous H5-specific hemagglutinin

    Seroconversion is defined as either a pre-vaccination titer \<1:10 and a post-vaccination titer \>/= 1:40 or a pre-vaccination titer \>/= 1:10 and a minimum four-fold rise in post-vaccination antibody titer

    Time frame: Day 8 through Day 57

07

Study locations

3 sites
  • Duke Vaccine and Trials Unit
    Durham, North Carolina 27703, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-0011, United States
  • Baylor College of Medicine
    Houston, Texas 77030-3411, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in May 2026, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2025
First posted
Jun 13, 2025
StartActual
Jun 12, 2025
Primary completionActual
May 22, 2026
CompletionActual
May 22, 2026
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019883
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Jun 12, 2025
Primary completion
May 22, 2026
Completion
May 22, 2026
Last update
Jun 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion